Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Triple meeting 2024 – Revolution shows selective KRAS promise
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
